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Abstract
Background: People aged 40–60 years with a family history (FH) of colorectal cancer (CRC) in 1st degree relatives
(FDRs) have a 2- to 4-fold increased risk of CRC compared to the average risk population. Therefore, experts
recommend starting CRC screening earlier for this high-risk group. However, information on prevalence of relevant
colonoscopic findings in this group is sparse, and no risk adapted screening offers are implemented in the German
health care system. For example, screening colonoscopy is uniformly offered from age 55 on, regardless of family
history. Thus, we initiated a multicenter epidemiological study - the RaPS study (Risk adapted prevention strategies
for colorectal cancer) – with the following aims: to determine the prevalence of having a FH of CRC in FDR in the
German population aged 40–54 years; to investigate the prevalence of colorectal neoplasms among people with a
FDR; and to develop risk-adapted prevention strategies for this high-risk group based on the collected information.
Methods/Design: A random sample of 160.000 persons from the general population aged 40–54 years from the
catchment areas of three study centers in Germany (Dresden, Munich and Stuttgart) are contacted to assess FH of
CRC by an online-questionnaire. Those with a FH of CRC in FDRs are invited to the study centers for individual
consultation regarding CRC prevention. Participants are asked to donate blood and stool samples and medical
records of colonoscopies will be obtained. Prevalence of CRC and its precursors will be evaluated. Furthermore,
genetic, epigenetic and proteomic biomarkers in blood and microbiomic biomarkers in stool will be investigated.
Risk markers and their eligibility for risk adapted screening offers will be examined.
Discussion: This study will provide data on the prevalence of colorectal neoplasms among persons with a FH
of CRC in the age group 40–54 years, which will enable us to derive evidence based screening strategies for
this high-risk group.
Trial registration: This trial was registered retrospectively in the German Clinical Trials Register (DRKS) on
29th of December 2016: German Clinical Trials Register DRKS-ID: DRKS00007842.
Keywords: Colorectal cancer, Early detection, Screening, Family history
* Correspondence: k.tikk@dkfz.de
Kaja Tikk and Korbinian Weigl share the first authorship.
†Kaja Tikk and Korbinian Weigl contributed equally to this work.
1Division of Clinical Epidemiology and Aging Research, German Cancer
Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg,
Germany
2German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tikk et al. BMC Cancer  (2018) 18:720 
https://doi.org/10.1186/s12885-018-4646-5
Background
Colorectal cancer (CRC) is the third most common cancer
globally, and the fourth most common cancer cause of
death [1]. There is increasing evidence that the burden of
the disease can be limited to a large extent by screening [2],
and screening programs are meanwhile implemented in an
increasing number of countries [3, 4]. It is well known that
people with a family history (FH) of CRC are at increased
risk of the disease [5] and guidelines commonly recom-
mend that first degree relatives of CRC patients should
undergo earlier and more intensive screening [6]. However,
data from large scale population-based studies on the
prevalence of FH of CRC according to age, sex and other
potential determinants, on the age and sex specific preva-
lence of colorectal neoplasms according to FH, on the use
of CRC screening offers by those with a FH, and on the
performance of potential noninvasive screening methods in
this high risk group are sparse. In order to address these
questions in detail, we initiated the RAPS study (Risk
adapted prevention strategies for colorectal cancer) in the
context of the German Cancer Consortium. Here, we de-
scribe the study design and summarize the study protocol.
Objectives
This study aims to provide empirical evidence for the
design and implementation of enhanced risk adapted
CRC screening strategies and screening coverage for
people with FH of CRC in Germany. In addition, the
aim is to identify and evaluate novel biomarkers for risk
stratification and early detection of CRC and its precur-
sors among people with a FH of CRC.
In particular, the following primary research questions
are addressed:
1. What is the prevalence of a history of CRC in 1st
and 2nd degree relatives in the German population
aged 40–54 years? To what extent are affected
people aware of their increased risk and possibilities
of early detection and prevention?
2. What are the prevalences of colorectal neoplasms
(CRC, advanced adenomas and non-advanced aden-
omas), overall and by number, size, location, histo-
pathological and molecular characteristics among
people aged 40–54 years with a 1st degree relative
(FDR) with CRC? How do these prevalences vary
according to age, sex and other risk factors, and ac-
cording to number, sex, and age at diagnosis of af-
fected 1st and 2nd degree relatives?
3. To what extent can genetic, epigenetic, proteomic
and microbiomic biomarkers predict the presence
of colorectal neoplasms among people with a FH of
CRC? To what extent can this information be used
for effective risk stratification and personalized,
targeted screening?
4. What are the implications for the need, design,
effectiveness and cost-effectiveness of special
screening offers for people with a positive family
history of CRC? In particular, the implications of
the findings for effective risk adapted, personalized
secondary prevention of CRC are to be worked out.
Methods/Design
The RAPS study is a multicenter cross-sectional study of
the general population in Germany. The recruitment of
the participants takes place in three large cities in
Germany (Dresden, Munich, Stuttgart) and the study is
conducted in two parts consisting of (i) an online-survey
and (ii) in-depth personal consultation and examination
(Fig. 1, study flow chart).
Part 1 - Online survey
For the first study part, random samples (n =
40,000-60,000) of the general population aged 40–54 from
the catchment areas of each of the 3 recruiting centers
(Dresden, Munich, Stuttgart) are drawn from local popula-
tion registration offices. The selected population is screened
for the presence of increased CRC risk due to FH by an on-
line questionnaire. From June 2015 onwards, invitation let-
ters with personalized six-digit passwords (consisting of
letters and numbers) which allow access to the online ques-
tionnaire are sent to 4000 to 6000 persons per recruitment
city on a monthly basis, with a total of 160,000 persons be-
ing invited to complete the online questionnaire. The invi-
tation letters include a scannable QR code which directly
leads to the online questionnaire. Prior to the access to the
questionnaire, participants have to confirm that they have
read the participants’ information including information
about data protection, which are provided online. After this,
an online-informed consent is obtained. Persons who are
not able or not willing to complete the online questionnaire
are offered a hard copy of the questionnaire as well as
printed copies of all necessary documents and a reply-paid
envelope. In this case, after written informed consent and
the ascertainment of completion of the questionnaire, the
data is transferred to the database by study data managers
in the coordinating center in Heidelberg. People who do
not respond to the first invitation for three weeks are con-
tacted two more times with reminders, each sent on aver-
age three weeks after the previous invitation.
After completion of the online questionnaire, all partici-
pants instantly receive personalized feedback regarding
their individual risk factors for CRC. Risk factors reported
by the participants are automatically processed and coded
after submission of the online questionnaire, and a com-
puter based algorithm is generated based on the informa-
tion about these risk factors. This automatically received
feedback, prepared in collaboration with the German
Cancer Information Service, provides information and
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recommendations regarding both common modifiable risk
factors for CRC prevention, including smoking, alcohol
consumption, body mass index, red meat intake, physical
activity, as well as non-modifiable risk factors such as age,
syndromes and diseases (e.g. Lynch syndrome, familial ad-
enomatous polyposis, and inflammatory bowel diseases).
Persons who complete hard-copies of the questionnaire re-
ceive the feedback with regular mail.
Part 2 - In-depth personal consultation and examination
in study centers
In addition to the feedback to their individual risk factors
for CRC prevention, participants reporting a FH of CRC
in a FDR automatically receive information on the second
part of the study. These participants are contacted again
either by letter, e-mail or by phone (if they provided a
valid e-mail-address or telephone number in their
online-questionnaire), and are offered to take part in an
individual consultation regarding CRC prevention and
examination regarding CRC risk in the study centers in
their catchment areas. During the consultation, performed
by trained gastroenterologists, persons are invited to par-
ticipate in the second part of the study which includes an
additional comprehensive questionnaire, the donation of
blood samples, stool samples and a qualitative fecal im-
munochemical test (FIT). In addition, if recommended by
gastroenterologists, participants are offered a screening
colonoscopy either in the study centers or by cooperating
private gastroenterologists in the study region.
Inclusion and exclusion criteria
Inclusion criteria for the first study part comprise (a) age
between 40 and 54 years, (b) living in the catchment areas
of the three study centers and being included in the random
samples drawn from the registration office, and (c) having
sufficient German skills to understand the participants’ in-
formation and to complete the online questionnaire.
Inclusion criterion for the second study part is having
a self-reported FH of CRC in at least one FDR as stated
in the online questionnaire. Persons who were diagnosed
with CRC prior to the study are excluded for the second
part of the study.
Data collection
Questionnaire data
The online questionnaire in the first study part consists of
questions about previously diagnosed diseases (e.g. cardio-
vascular diseases, diabetes, cancer), previously conducted
prevention examinations (e.g. general health examination,
skin cancer screening, mammography / prostate-specific
antigen testing), previously conducted screening examina-
tions for the colon (FIT, lower gastrointestinal exam, col-
onoscopy), FH of CRC in FDR (i.e. mother, father, sibling;
if FH in FDR was present, age of diagnosis was obtained),
FH of CRC in second-degree relative (SDR), lifestyle fac-
tors (e.g. smoking, alcohol consumption, nutrition, phys-
ical activity, intake of non-steroidal anti-inflammatory
drugs/aspirin, intake of hormone replacement therapy for
women) and personal information (such as sex, age,
height, weight, education, household size). If participants
state having had previous colonoscopies, permission to re-
quest colonoscopy and histological reports from the treat-
ing physician is asked for.
Participants of the second study part are asked to
complete an additional questionnaire with a more com-
prehensive ascertainment of the individuals’ family
Fig. 1 Study Flow Chart
Tikk et al. BMC Cancer  (2018) 18:720 Page 3 of 6
history (e.g. age at diagnosis for relatives, how many rel-
atives are affected, total family size).
Blood and stool samples
After individual consultation and signed informed con-
sent for the second part of the study, blood samples (2 ×
9 ml in serum vacutainer, 2 × 9 ml in EDTA vacutainer,
36 ml in total) are drawn immediately at the study cen-
ters. All blood samples are processed within two hours
after donation according to a standardized operation
procedure. After blood sampling, both serum vacutai-
ners and one EDTA vacutainer are centrifuged for ten
minutes with 2500 g at 4 °C, before they are stored at −
80 °C in 0.5 and 1 ml aliquots. The second EDTA vacu-
tainer is centrifuged for 20 min with 1300 g at 4 °C. The
supernate is further centrifuged for ten minutes with
15,000 g at 10 °C. The resulting supernate is stored at −
80 °C in 1 ml aliquots.
The participants receive a prepared stool sampling kit,
which consists of two stool collection tubes including
RNA later and one FIT (ImmoCARE-C, cut-off 50 ng/
ml, Care diagnostic©). The FIT used in this study is a
commercially available and validated test. The partici-
pants are asked to collect all stool samples from the
same stool (no dietary restrictions, approximately 1 g
each) and send it via regular mail to the coordinating
center in Heidelberg with a prepaid envelope. If a par-
ticipant decides to undergo colonoscopy, stool samples
are taken before bowel preparation. The FIT is analyzed
in the laboratory of the coordinating center in Heidel-
berg, and participants are informed about the test result
in case of a positive FIT.
Data collection and documentation in the coordinating
center
All collected data and blood samples are gradually trans-
ferred from study centers to a central databank in the
coordinating center in Heidelberg. The information col-
lected from colonoscopy and histology reports is entered
into a standardized study database by trained staff in the
coordinating center, using double data entry by two in-
dependent staff members. Data entries are checked for
inconsistencies through comparison of the correspond-
ing data sets. In case of differences in data sets, original
reports are checked for validation.
Documentation of information collected in the ques-
tionnaire (part 2) include automated scanning of the
questionnaires, optical verification of the scans by
trained staff, and comprehensive plausibility checks prior
to statistical analysis. All collected information is stored
at the coordinating center.
The blood and stool samples are stored at − 80 °C in a
central biorepository at the coordinating center until fur-
ther analyses.
Sample size calculation
Expected sample size for study part 1 includes 3 × 10,000
= 30,000 online-questionnaire responses, which would en-
able the most comprehensive analyses of the occurrence
of patterns of familial CRC risk on the population level
available to date. These analyses will enable the evaluation
of risk adapted screening strategies even for small, specific
risk groups with the necessary precision.
Expected sample size for research questions 2 and 3
will include around 3 × 400 = 1200 women and men aged
40–54 with CRC in a FDR for whom extensive question-
naires, colonoscopy and histopathology reports, as well
as biospecimens (blood, stool) will be available. With an
expected prevalence of advanced neoplasms detected
and removed at colonoscopy of 10% (n = 120), approxi-
mately half of which would be expected to develop into
clinically manifest CRC within 10 years in the absence of
detection and removal, this study will prevent a men-
tionable number of CRCs occurring at relatively young
age. The sample size will furthermore ensure the estima-
tion of the prevalence of colorectal neoplasms, as well as
calculation of performance indicators of risk discrimin-
ation and risk stratification (e.g. area under the curve,
numbers needed to screen) with adequate precision,
even for relevant subgroups defined by age, sex, and
other risk factors.
In the light of the fact that the current study is the
first large scale epidemiological study trying to use this
two-stepped approach for recruiting the participants
with FH of CRC and that the current evidence regarding
associated response rates is very limited, our above de-
scribed expected sample size is calculated based on edu-
cated guess. To ensure the targeted sample size, several
efforts to drive the response rates towards our expect-
ation are considered and actively followed (e.g. increase
of invited study population or reminders to participate).
Statistical analysis
Prevalence of CRC and its precursors (in particular ad-
vanced adenomas and non-advanced adenomas as well
as serrated polyps, overall and according to number, size,
location, and histopathological characteristics) will be
evaluated according to age and sex of participants, as
well as number, type and age at diagnosis of affected 1st
and 2nd degree relatives and other risk factors. Based on
these results, implications for screening strategies (in-
cluding cost-effectiveness) will be evaluated. In particu-
lar, the expected number of prevented CRCs and CRC
deaths, and the expected cost savings by early detection
and prevention of CRCs will be computed and related to
the costs of screening at ages 40–54 in this high risk
group. Recommendations will be worked out for risk
adapted CRC screening offers for the high risk popula-
tion of people with a positive FH of CRC.
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Discussion
We initiated a large-scale, two-phased, multicenter
population-based epidemiological study within the
German Cancer Consortium in order to provide solid em-
pirical evidence for risk adapted, enhanced CRC screening
strategies for persons with a FH of CRC. This study pro-
vides, for the first time in Germany, the necessary data for
deriving evidence based screening guidelines for the high
risk group of people with a FH of CRC. Active engage-
ment of the investigators in guideline and policy develop-
ment on the national and international level will ensure
translation of results into practice.
Furthermore, due to detection and removal of advanced
neoplasms at colonoscopy of participants in this study, it
is expected to prevent a number of cases of CRC at rela-
tively young age. If translated in risk adapted screening of-
fers on the national level, a substantial proportion of the
approximately 15,000 CRCs occurring before age 65 in
Germany annually and their treatment costs could be pre-
vented. The comprehensive risk factor, genetic, epigenetic,
proteomic and microbiomic profiling will provide the
basis for effective risk stratification and risk adapted
screening strategies in this high risk population.
In order to further enhance the empirical basis for risk
adapted, personalized prevention in this high risk group,
the potential for enhanced risk stratification based on
novel genetic and proteomic biomarkers from blood sam-
ples and microbiomic biomarkers from stool sample will
be evaluated. For genetic profiling, Infinium® Global
Screening Array by Illumina, which covers > 700,000 sin-
gle nucleotide polymorphisms (SNPs) will be used. Imput-
ation based on whole genome sequencing data will yield
several millions SNPs which can be analyzed accordingly
[7]. For high throughput high dimensional proteomic ana-
lysis, the newly launched protein biomarker panels from
OLINK Bioscience (Sweden) will be used, allowing to
analyze a large number of proteins related to different bio-
logical mechanisms, such as angiogenesis, cell-cell signal-
ing, growth control and inflammation. For microbiome
analysis, DNA extraction with 16S rRNA gene sequencing
and shotgun metagenomics sequencing at the European
Molecular Biology Laboratory (EMBL) GeneCore facility,
using state-of-the-art sequencing techniques with a special
workflow for microbiomics, will be applied.
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